Press releases and official statements

 

SAKK becomes a partner of SPHN

Press release, June 6, 2024. Available languages:
Sinkende Therapiekosten und reduzierte Nebenwirkungen

Sinkende Therapiekosten und reduzierte Nebenwirkungen

Press release, June 6, 2024. Available languages:

Vincent Gruntz is to be the new CEO of SAKK

Press release, May 31, 2024. Available languages:

National Councilor Marianne Binder-Keller and Dr. Christian Rathgeb elected to the SAKK Board

Press release, May 5, 2022. Available languages:

Hans Rudolf Keller is the new CEO of SAKK

Press release, January 27, 2022. Available languages:

Medienmitteilung des Patientenrats der SAKK: NEIN zum Tier- und Menschenversuchsverbot

January 17, 2022. Available languages:

Oasmia Pharmaceutical AB: First Patient enrolled in the SAKK Investigator-Initiated Phase 1b trial of Docetaxel Micellar in Advanced Prostate Cancer

Press release, June 10, 2021. Available languages:

Patienten, die in Studien behandelt werden, haben ein besseres Outcome

In Gespräch mit Prof. Dr. med. Roger von Moos.
Download Deutsch.
OncoMag 4/2020.

Joint statement on the popular initiative "Yes to the ban on animal and human experiments”

June 4, 2020. Available languages:

Professor Aron Goldhirsch (1946-2020): An exeptional Oncologist, Scientist and Teacher

March 04, 2020. Available languages:

Establishing a SAKK Working Group for Cellular Therapies

Press release, December 12, 2019. Available languages:

SAKK / Celgene «Life Grant» 2019

Press release, November 22, 2019. Available languages:

Kinderspitäler beklagen schwindende Pharmagelder

NZZ am Sonntag, November 17, 2019. Available languages:

Pascal Coullery: Der Forschungsbegriff des Krankenversicherungsgesetzes

Gutachten über die Rechtmässigkeit abgelehnter Kostenübernahme durch die Krankenkassen.

Download Deutsch

Lurbinectedin data in Progressive Malignant Pleural Mesothelioma presented at ESMO (SAKK 17/16)

Download english

Unispitäle steigen in Krebstherapie ein

NZZ am Sonntag, July 28, 2019. Available languages:

Krebs noch zielgerichteter behandeln

Article from April 10, 2019 in Planet Gesundheit

InnoMedica Holding AG: First cancer patient treated with liposomal doxorubicin

Press release, 10 January 2019. Available languages:

Extension of the research network to regional hospitals

Press release, 8 January 2019. Available languages:

SAKK 17/16 Phase II trial of lurbinectedin in progressive mesothelioma

Press release, 17 December 2018. Available languages:

Besser, günstiger, aber unrentabel

Der Bund, 23 November 2018. Available languages:

The 2018 GIST award goes to Dr. med. Michael Montemurro, CHUV, Lausanne and SAKK

Press release, 22 November 2018. Available languages:

Gute Medikamente, böse Pharma

NZZ article, 18 July 2018. Available languages:

InnoMedica bringt erstes Krebsmedikament mit der SAKK in die Schweizer Spitäler

Press release, 2 March 2017. Available languages:

Further strengthening the network of cancer centres in Switzerland

Press release, 1 July 2016. Available languages:

Swiss cancer research network establishes patient representative board

Press release, 3 December 2015. Available languages: 

Patientenorientierte klinische Forschung in der Schweiz: 5 prioritäre Handlungsfelder

Fields of action. Available languages: